Clinical Trial Update: Pazopanib in Advanced Gastrointestinal Stromal Tumors Refractory to Imatinib and Sunitinib [Phase 2]

View source ↗

Summary

This document provides an update on a Phase 2 trial of pazopanib in advanced gastrointestinal stromal tumors refractory to imatinib and sunitinib, which has com…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastrointestinal Stromal Tumors

Drugs mentioned

• Votrient (Pazopanib)

Snippet

Sponsor: Scandinavian Sarcoma Group | Conditions: Gastrointestinal Stromal Tumors | Phase 2 | Status: COMPLETED